Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(12):1655–1660. doi: 10.1038/bjc.1997.613

Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients.

F Formelli 1, E Cavadini 1, L Mascheroni 1, F Belli 1, N Cascinelli 1
PMCID: PMC2228192  PMID: 9413958

Abstract

The pharmacokinetics of 13-cis-retinoic acid (13cisRA) and its effects on retinol plasma levels were investigated after the first and the last doses in melanoma patients, who participated in a study run to assess tolerance over a long period of a treatment schedule of 13cisRA associated with recombinant interferon alpha2a (rIFN-alpha2a). Melanoma patients with regional node metastases after radical surgery were randomized to be treated for 3 months with rIFN-alpha2a, 3 x 10(6) IU s.c. every other day, associated with oral 13cisRA at doses of 20 mg day(-1) (five patients) or 40 mg every other day (seven patients). Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml(-1) (i.e. 1.3 and 2.1 microM) after the 20 and 40 mg dose respectively. The average half-life (t(1/2)) was approximately 30 h. The maximum concentration, the t(1/2) and the area under the concentration-time curves from 0 to 48 h (AUC(0-48)) of 13cisRA did not change after multiple dosing, whereas the AUC(0-48) of its major blood metabolite, 4-oxo-13-cis-retinoic acid, increased. Immediately after 13cisRA treatment, retinol plasma levels started to decline and they reached the lowest values (approximately 20% reduction) shortly after the time of maximum 13cisRA concentrations (i.e. 4-12 h after drug intake). Afterwards, values returned to baseline. The amount of retinol reduction in time was correlated with 13cisRA maximum concentrations.

Full text

PDF
1655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berni R., Clerici M., Malpeli G., Cleris L., Formelli F. Retinoids: in vitro interaction with retinol-binding protein and influence on plasma retinol. FASEB J. 1993 Sep;7(12):1179–1184. doi: 10.1096/fasebj.7.12.8375617. [DOI] [PubMed] [Google Scholar]
  2. Brazzell R. K., Vane F. M., Ehmann C. W., Colburn W. A. Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol. 1983;24(5):695–702. doi: 10.1007/BF00542225. [DOI] [PubMed] [Google Scholar]
  3. Cascinelli N., Bufalino R., Morabito A., Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994 Apr 9;343(8902):913–914. doi: 10.1016/s0140-6736(94)90030-2. [DOI] [PubMed] [Google Scholar]
  4. Colburn W. A., Gibson D. M., Wiens R. E., Hanigan J. J. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983 Nov-Dec;23(11-12):534–539. doi: 10.1002/j.1552-4604.1983.tb01800.x. [DOI] [PubMed] [Google Scholar]
  5. Collins M. D., Tzimas G., Hummler H., Bürgin H., Nau H. Comparative teratology and transplacental pharmacokinetics of all-trans-retinoic acid, 13-cis-retinoic acid, and retinyl palmitate following daily administrations in rats. Toxicol Appl Pharmacol. 1994 Jul;127(1):132–144. doi: 10.1006/taap.1994.1147. [DOI] [PubMed] [Google Scholar]
  6. Fierlbeck G., Schreiner T., Rassner G. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother. 1995 Mar;40(3):157–164. doi: 10.1007/BF01517347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Formelli F., Carsana R., Costa A., Buranelli F., Campa T., Dossena G., Magni A., Pizzichetta M. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res. 1989 Nov 1;49(21):6149–6152. [PubMed] [Google Scholar]
  8. Goodman G. E., Einspahr J. G., Alberts D. S., Davis T. P., Leigh S. A., Chen H. S., Meyskens F. L. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res. 1982 May;42(5):2087–2091. [PubMed] [Google Scholar]
  9. Khoo K. C., Reik D., Colburn W. A. Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol. 1982 Aug-Sep;22(8-9):395–402. doi: 10.1002/j.1552-4604.1982.tb02692.x. [DOI] [PubMed] [Google Scholar]
  10. Lippman S. M., Kavanagh J. J., Paredes-Espinoza M., Delgadillo-Madrueño F., Paredes-Casillas P., Hong W. K., Holdener E., Krakoff I. H. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst. 1992 Feb 19;84(4):241–245. doi: 10.1093/jnci/84.4.241. [DOI] [PubMed] [Google Scholar]
  11. Lippman S. M., Parkinson D. R., Itri L. M., Weber R. S., Schantz S. P., Ota D. M., Schusterman M. A., Krakoff I. H., Gutterman J. U., Hong W. K. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992 Feb 19;84(4):235–241. doi: 10.1093/jnci/84.4.235. [DOI] [PubMed] [Google Scholar]
  12. Lotan R., Dawson M. I., Zou C. C., Jong L., Lotan D., Zou C. P. Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and alpha-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res. 1995 Jan 15;55(2):232–236. [PubMed] [Google Scholar]
  13. Marth C., Widschwendter M., Daxenbichler G. Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and interferons in breast cancer cells. J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):123–126. doi: 10.1016/0960-0760(93)90065-5. [DOI] [PubMed] [Google Scholar]
  14. Sass J. O., Masgrau E., Saurat J. H., Nau H. Metabolism of oral 9-cis-retinoic acid in the human. Identification of 9-cis-retinoyl-beta-glucuronide and 9-cis-4-oxo-retinoyl-beta-glucuronide as urinary metabolites. Drug Metab Dispos. 1995 Sep;23(9):887–891. [PubMed] [Google Scholar]
  15. Schaber B., Mayer P., Schreiner T., Rassner G., Fierlbeck G. Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res. 1994 Oct;4(5):319–326. [PubMed] [Google Scholar]
  16. Triozzi P. L., Walker M. J., Pellegrini A. E., Dayton M. A. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest. 1996;14(4):293–298. doi: 10.3109/07357909609012154. [DOI] [PubMed] [Google Scholar]
  17. Villablanca J. G., Khan A. A., Avramis V. I., Seeger R. C., Matthay K. K., Ramsay N. K., Reynolds C. P. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995 Apr;13(4):894–901. doi: 10.1200/JCO.1995.13.4.894. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES